Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21372065 | 0.78 | MAPT (0.65) | TP53MAPTKDM4ENPC1RAB9A | |
| SCHEMBL9887574 | 0.75 | ADRB2 (0.55) | TP53MAPTKDM4EADRB2 | |
| SCHEMBL21440747 | 0.75 | TP53 (0.48) | TP53MAPTKDM4ENPC1RAB9A | |
| SCHEMBL15383744 | 0.75 | TP53 (0.53) | TP53MAPTKDM4ENPC1RAB9A | |
| SCHEMBL1299054 | 0.75 | TP53 (0.48) | TP53MAPTKDM4ENPC1RAB9A | |
| SCHEMBL15305929 | 0.75 | TP53 (0.48) | TP53MAPTKDM4ENPC1RAB9A | |
| SCHEMBL19543315 | 0.72 | MAPT (0.50) | TP53MAPTKDM4ENPC1RAB9A | |
| SCHEMBL25457269 | 0.71 | HRH3 (0.59) | TP53MAPTKDM4E | |
| SCHEMBL21130123 | 0.71 | TP53 (0.44) | TP53MAPTKDM4ENPC1RAB9A | |
| SCHEMBL24267772 | 0.71 | TP53 (0.44) | TP53MAPTKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732001-B2 | Methods of incorporating an amino acid comprising a BCN group into a polypeptide using an orthogonal codon encoding it and an orthogonal pylrs synthase | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11732001-B2 | Methods of incorporating an amino acid comprising a BCN group into a polypeptide using an orthogonal codon encoding it and an orthogonal pylrs synthase | COASY, BCAT1, FARSA | TP53 3363/4885MAPT 4715/4885KDM4E 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.